Strong funding SpliceBio recently secured $135M in a Series B led by EQT Life Sciences with participation from Sanofi Ventures and Roche Venture Fund, alongside a total funding track record of $194M. This indicates growing financial capacity to engage in strategic partnerships, expand pipelines, and invest in scalable contract services or collaboration-based opportunities.

Strategic collaborations The company has a history of high-profile collaborations, including a past partnership with Spark Therapeutics and current investor support from major biopharma players. This suggests openness to co-development, licensing, and contract research opportunities with pharma and specialty gene therapy developers.

Gene splicing platform SpliceBio leverages proprietary Protein Splicing to develop gene therapies, offering a differentiated delivery technology. This positions them to seek specialized service providers, manufacturing partners, and regulatory/compliance consultants focused on advanced biologics and gene therapy modalities.

Leadership and talent Key appointments in leadership (CMO Aniz Girach joining in 2024; former CDO David Favre joins in 2023) indicate a maturation of the organization and readiness to scale clinical programs. This creates opportunities for executive-focused partnerships, advisory roles, and clinical development collaborations.

Geographic and market momentum Barcelona-based SpliceBio is actively expanding its pipeline to address diseases like Stargardt, signaling a progressive market entry in genetic medicines with the backing of international investors. This suggests openings for regional partnerships, manufacturing access, and market-entry support services in Europe and beyond.